Business
Result of Meeting and TVR
Abingdon Health PLC announced that all resolutions proposed at its General Meeting on October 30, 2025, were duly passed, satisfying a condition for completion of its Fundraising. Application has been made for admission of 57,441,821 new Ordinary Shares to trading on AIM, expected to commence around October 31, 2025, at 8:00 a.m. Following admission, the Company's issued ordinary share capital will comprise 251,072,642 Ordinary Shares, representing the total number of voting rights. Executive Chairman Chris Hand purchased 500,000 ordinary shares at 6 pence per share, increasing his holding to 13,678,467 shares, representing 5.4% of the enlarged share capital. Quality and Regulatory Director Candice Vendettuoli purchased 33,333 ordinary shares at 6 pence per share, holding 0.01% of the enlarged share capital. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n \nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.\n \n \n\n \n30 October 2025\n \nAbingdon Health plc\n \n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \nResult of General Meeting and Total Voting Rights\n \nAbingdon Health plc (AIM: ABDX) a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, is pleased to announce that, at the General Meeting held earlier today, the Resolutions set out in the Notice of General Meeting contained in the Circular dated 14 October 2025 were duly passed.\n \nCapitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement made at 5:04 p.m. on 13 October 2025, unless the context requires otherwise.\n \nResult of Meeting\n \nDetails of the results of the voting at the General Meeting, including the number of votes for and against the Resolutions proposed, and the number of votes withheld, are set out below. The Resolutions were proposed and passed as one ordinary resolution and one special resolution.\n \n\n\n\n\nResolution\n\n\nFor\n\n\nAgainst\n\n\nWithheld\n\n\n\n\nVotes\n\n\n% of votes cast\n\n\nVotes\n\n\n% of votes cast\n\n\nVotes\n\n\n\n\n1. Authority to allot shares\n\n\n 81,408,856\n\n\n 99.82\n\n\n 144,292\n\n\n 0.18\n\n\n 23,747\n\n\n\n\n2. Disapplication of pre-emption rights\n\n\n 81,247,542\n\n\n 99.66\n\n\n 273,311\n\n\n 0.34\n\n\n 56,042\n\n\n\n\n \nThe total number of votes received were 163,074,001. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.\n \nThe passing of the Resolutions is one of the conditions to completion of the Fundraising, and as a result of the votes cast in their favour, that particular condition has been satisfied. Completion of the Fundraising remains conditional upon Admission, which is expected to occur on or around 31 October 2025.\n \nAdmission and Total Voting Rights\n \nApplication has been made to the London Stock Exchange ...